Publications
-
Correlates of HIV testing history among urban youth recruited through venue-based testing in 15 US
Citation: Straub DM, Arrington-Sanders R, Harris DR, Willard N, Kapogiannis B, Emmanuel P, Futterman D, Ellen JM, and the ATN. Correlates of HIV testing history among urban youth recruited through venue-based testing in 15 US cities. Sex Transm Dis. 2011 Aug;38(8):691-696. (ATN 016b) PMID: 21758020; PMCID 3155007
Date: 08/01/2011
Community-based intervention to increase HIV testing and case detection in people aged 16-32 years
Citation: Sweat M, Morin S, Celentano D, Mulawa M, Singh B, Mbwambo J, Kawichai S, Chingono A, Khumalo-Sakutukwa G, Gray G, Richter L, Kulich M, Sadowski A, Coates T; Project Accept study team. Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis. 2011 Jul;11(7):525-32. Epub 2011 May 3. PMID: 21546309; PMCID: PMC3156626
Date: 07/01/2011
When a serious adverse event in research occurs, how do other volunteers react?
Citation: Kennedy CE, Kass N, Myers RK, Fuchs EJ, Flexner C. When a serious adverse event in research occurs, how do other volunteers react? J Empir Res Hum Res Ethics. 2011 Jun;6(2):47-56. doi: 10.1525/jer.2011.6.2.47.
Date: 06/15/2011
Use of antineoplastic agents in patients with cancer who have HIV/AIDS
Citation: Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011 Sep;12(9):905-12. doi: 10.1016/S1470-2045(11)70056-0. Epub 2011 May 12
Date: 05/12/2011
Association between systemic inflammation and incident diabetes mellitus in HIV-infected patients
Citation: Brown TT, Tassiopoulos K, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes mellitus in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010 Oct;33(10):2244-9. PMID: 20664016. PMCID: PMC2945167.
Date: 10/01/2010
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected
Citation: Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, Godfrey C, Hirsch M, Kuritzkes DR, Gulick RM. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr. 2010 Aug;54(5):470-6.
Date: 08/15/2010
Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort
Citation: Brown TT, Smurzynski M, Wu K, Bosch RJ, McComsey GA. Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort. Antivir Ther. 2009;14(6):853-8. doi: 10.3851/IMP1300.
Date: 05/06/2010
Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist
Citation: Crawford KW1, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C; ACTG A5211 Study Team. Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211). J Acquir Immune Defic Syndr. 2010 Apr;53(5):598-605. doi: 10.1097/QAI.0b013e3181c9caac.
Date: 04/15/2010
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive
Citation: Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, Rosenkranz SL, Kmack A, Ferguson E, Dehlinger M, Mildvan D; ACTG A5073 Study Team. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010 Apr 1;50(7):1041-52. doi: 10.1086/651118.
Date: 04/01/2010
Identification of ongoing HIV-1 replication in residual viremia during recombinant HIV-1 poxvirus
Citation: Shiu C, Cunningham CK, Greenough T, Muresan P, Sanchez-Merino V, Carey V, Jackson JB, Ziemniak C, Fox L, Belzer M, Ray SC, Luzuriaga K, Persaud D. Identification of ongoing HIV-1 replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on Durable Suppressive HAART. J Virol. 2009;83(19):9731-42. Epub 2009 Jul 15. PMID: 19605490; PMCID: PMC2748010
Date: 07/15/2009
- ‹ First < 23 24 25 26 >